Since the toxic effects of telomerase can be rescued by blocking fork reversal, our results raise the possibility that progression of HHS could be attenuated with PARP inhibitors, which are currently in clinical use for the treatment of homologous recombination-deficient breast and ovarian cancers. This evidence concerns the gene PARP1 and ovarian carcinoma.